Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02905435 · ClinicalTrials.gov registry record · NA
Assessment of Safety and Effectiveness of Biodegradable Temporizing Matrix in the Treatment of Deep Burn Skin Injuries
A NA study of Burns, sponsored by PolyNovo Biomaterials Pty.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 5
- Study locations
NCT02905435: Completed NA study of Burns, sponsored by PolyNovo Biomaterials Pty.
NCT02905435 is a NA study of Burns that has completed, run by PolyNovo Biomaterials Pty. The registered enrollment target is 15 participants, below the 83-participant average among 36 other Burns trials with a reported enrollment target (82% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02905435, a NA study of Burns, has completed, sponsored by PolyNovo Biomaterials Pty.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multi-center, single arm, traditional feasibility study to allow a preliminary assessment of the safety and effectiveness of a new method of treating skin burns using Biodegradable Temporizing Matrix (BTM).
Primary Outcome
Percentage of total body surface area (%TBSA) of BTM that has adhered at time of skin grafting, divided by the %TBSA treated with BTM, then multiplied by 100 to express as a percentage. Calculated per study lesion and averaged per participant.
Conditions Studied
Interventions
- DEVICE Biodegradable Temporizing Matrix
Study Locations (5)
Arizona
- Arizona Burn Center at Maricopa Medical Center - Phoenix
California
- University of California Davis Medical Center - Sacramento
Florida
- Tampa General Hospital - Tampa
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Tennessee
- University of Tennessee Health Science Center - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-11-05 |
| Est. Completion | 2019-09-18 |
| Phase | NA |
What the finished NCT02905435 record still lists
NCT02905435 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 83-participant average among 36 other Burns trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Burns appearing as the primary indexed condition, and to 1 intervention - of which Biodegradable Temporizing Matrix is the first listed.
NCT02905435 lists 5 locations in 5 states (Arizona, California, Florida).
Frequently Asked Questions
What is clinical trial NCT02905435 about?
NCT02905435 is a clinical study titled "Assessment of Safety and Effectiveness of Biodegradable Temporizing Matrix in the Treatment of Deep Burn Skin Injuries". This is a multi-center, single arm, traditional feasibility study to allow a preliminary assessment of the safety and effectiveness of a new method of treating skin burns using Biodegradable Temporizing Matrix (BTM).
What is the current status of trial NCT02905435?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2016-11-05. Estimated completion is 2019-09-18.
What conditions does trial NCT02905435 study?
This clinical trial studies the following conditions: Burns.
What interventions are being tested in trial NCT02905435?
The interventions under investigation include: Biodegradable Temporizing Matrix (DEVICE).
Who is sponsoring clinical trial NCT02905435?
This trial is sponsored by PolyNovo Biomaterials Pty, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02905435 being conducted?
This trial has 5 study locations across Arizona, California, Florida, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burns
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02905435's enrollment target sits among peer trials
15 29th of 36 higher than 7 of 36 other Burns trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Burns trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds
RECRUITING · NA
-
Impact of a Telerehabilitation Program With Technology Enhancement on Post-burn Recovery
RECRUITING · NA
-
Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns
ACTIVE NOT RECRUITING · NA
-
Conditioning & Open-Label Placebo (COLP) for Opioid Management in Intensive Inpatient Rehabilitation
ACTIVE NOT RECRUITING · NA
-
Virtual Reality in Burn Pain Management
COMPLETED · NA
-
Randomized Control Trial of CO2 Laser to Treat Hypertrophic Burn Scar
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI